Business Standard

Wednesday, January 01, 2025 | 07:39 AM ISTEN Hindi

Notification Icon
userprofile IconSearch

Cipla gains 3% post USFDA approval for its generic HIV drug

The stock up 3% at Rs 622 on the BSE in early morning trade and is 6.6% away from its 52-week high of Rs 663 touched on November 7, 2017.

Cipla gains 3% on USFDA approval for generic HIV drug
Premium

SI Reporter Mumbai
Shares of Cipla were up 3% at Rs 622 per share on the BSE in early morning trade after the company said that it has received approval from the US Food and Drug Administration (USFDA) to market Efavirenz tablets, used to treat HIV-1 infections in adults.

The stock of pharmaceutical company is 6.6% away from its 52-week high of Rs 663 touched on November 7, 2017 on the BSE.

“The company has received final approval for its Abbreviated New Drug Application (ANDA) for Efavirenz tablets 600mg from the United States Food and Drug Administration (USFDA),” Cipla said in a

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in